Company Filing History:
3 out of 10 
1 out of 5 
1 out of 685 
Years Active: 2009-2018
Title: The Innovative Contributions of Shu-Hua Lee
Introduction
Shu-Hua Lee is a prominent inventor based in Taipei, Taiwan. He has made significant contributions to the field of cancer treatment through his innovative research and development of antibody-drug conjugates. With a total of 4 patents, his work has the potential to impact therapeutic strategies for various cancers.
Latest Patents
One of his latest patents is focused on anti-folate receptor alpha (FRA) antibody-drug conjugates. This invention provides a hydrophilic self-immolative linker that enhances the efficacy of cancer treatments. Another notable patent involves antibodies that recognize a carbohydrate-containing epitope on CD-43 and CEA expressed on cancer cells. This invention aims to induce apoptosis in nonhematopoietic cancer cells without the need for cytotoxin conjugation, showcasing a novel approach to cancer therapy.
Career Highlights
Shu-Hua Lee has worked with several companies, including BioAlliance C.V. and Abgenomics International Inc. His experience in these organizations has contributed to his expertise in developing innovative solutions for cancer treatment.
Collaborations
Throughout his career, Shu-Hua Lee has collaborated with notable colleagues such as Rong-Hwa Lin and Shih-Yao Lin. These partnerships have fostered a collaborative environment that enhances the development of groundbreaking inventions.
Conclusion
Shu-Hua Lee's contributions to the field of cancer research through his patents and collaborations highlight his role as an influential inventor. His innovative approaches have the potential to transform cancer treatment methodologies and improve patient outcomes.